RxDoctor Payments Data

Patricia Doolin

Family · Columbia, KYNPI 1427549559

Payments from drug & device makers

$2,478in general payments, 2019–2025

Across 154 payments — averaging $16.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axsome Therapeutics, Inc.$471
  • AbbVie$407
  • Alkermes, Inc.$365
  • AstraZeneca$226
  • Vanda Pharmaceuticals Inc.$182
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$135
  • plus $692 from 17 others

What the payments were for

  • Food & beverage$2,478100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,478 in reported general payments places this provider in the 80th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide155$166,191
FarxigaDapagliflozin Propanediol152$134,274
OzempicSemaglutide79$87,170
JardianceEmpagliflozin67$51,002
EliquisApixaban60$46,705
TrulicityDulaglutide33$31,699
LinzessLinaclotide48$25,746
RexultiBrexpiprazole12$24,719
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$21,889
VraylarCariprazine Hcl11$21,037
XareltoRivaroxaban24$15,277
JanuviaSitagliptin Phosphate22$14,778
MyrbetriqMirabegron26$14,363
DapagliflozinDapagliflozin Propanediol28$13,212
Nurtec OdtRimegepant Sulfate12$13,152

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$93$197,889188 claims
AstraZenecaFarxiga, Breztri Aerosphere$226$156,163181 claims
Novo NordiskOzempic$50$87,17079 claims
PfizerEliquis, Nurtec Odt$103$59,85772 claims
Boehringer IngelheimJardiance$50$51,00267 claims
AbbVieLinzess, Vraylar$407$46,78259 claims
Otsuka America Pharmaceutical, Inc.Rexulti$27$24,71912 claims
MerckJanuvia$27$14,77822 claims
Astellas Pharma US IncMyrbetriq$15$14,36326 claims
GSKTrelegy Ellipta$67$12,78316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,374 family providers in Kentucky.

Other family in Columbia

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →